CLINICAL DATA INC 4
4 · CLINICAL DATA INC · Filed Apr 15, 2011
Insider Transaction Report
Form 4
BELBEL CAESAR J
EVP, Chief Legal Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2011-04-13$13.05/sh−50,000$652,500→ 0 totalExercise: $16.95Exp: 2018-04-17→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-04-13$21.22/sh−65,000$1,379,300→ 0 totalExercise: $8.78Exp: 2018-12-22→ Common Stock (65,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-04-13$26.79/sh−1,059$28,371→ 0 totalExercise: $3.21Exp: 2013-05-07→ Common Stock (1,059 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-04-13$18.07/sh−75,000$1,355,250→ 0 totalExercise: $11.93Exp: 2015-10-17→ Common Stock (75,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-04-13$17.63/sh−90,000$1,586,700→ 0 totalExercise: $12.37Exp: 2016-05-12→ Common Stock (90,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-04-13$19.27/sh−4,545$87,582→ 0 totalExercise: $10.73Exp: 2016-06-22→ Common Stock (4,545 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-04-13$15.01/sh−45,000$675,450→ 0 totalExercise: $14.99Exp: 2017-06-14→ Common Stock (45,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-04-13$15.77/sh−12,000$189,240→ 0 totalExercise: $14.23Exp: 2015-09-23→ Common Stock (12,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-04-13$11.61/sh−75,000$870,750→ 0 totalExercise: $18.39Exp: 2019-12-21→ Common Stock (75,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-04-13$13.46/sh−75,000$1,009,500→ 0 totalExercise: $16.54Exp: 2020-12-22→ Common Stock (75,000 underlying)
Footnotes (1)
- [F1]This option, whether fully vested or not, was terminated upon the completion of the merger of Magnolia Acquisition Corp. with and into Clinical Data, Inc. pursuant to the Agreement and Plan of Merger dated February 22, 2011, as amended on April 4, 2011. Pursuant to the Agreement and Plan of Merger, the option was converted into the right to receive $30.00 per share (minus the exercise price of the option) in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones, subject to any applicable tax withholdings.